Swedish–British pharma giant focused on oncology, cardiovascular, immune and respiratory diseases
Insilico Medicine has reported that rentosertib reduced biological age on six AI 'aging clocks' in a midstage trial, while separate studies have shown failures or mixed results for cardiovascular drugs: pelacarsen did not cut heart attacks or strokes, del-desiran produced no meaningful hand-strength benefit in myotonic dystrophy, and ziltivekimab trials have been stopped.
Arm CEO Rene Haas says AI will help cure cancer in readers’ lifetimes and will fuel humanoid robots, but chip shortages and memory constraints threaten timelines. He describes an “absolutely supply-constrained environment” and calls for more fabs while noting broader AI demand for chips.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Anthropic is launching an internal drug-discovery program to develop AI tools for life sciences, focusing on neglected diseases. The effort aims to create drug-discovery capabilities in-house and partner with industry, while navigating the costly regulatory path and uncertain clinical development timelines.
The UK–US pharmaceutical deal has led to a BMJ analysis predicting the NHS will divert billions to fund new medicines, risking hundreds of thousands of excess deaths by 2036, with the toll higher if social care funding is included.
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.
A UK-Oxford vaccine candidate has begun Phase I testing in healthy volunteers to assess safety and immune response. The work leverages the same technology as the Oxford–AstraZeneca Covid jab. Trials are planned in Africa with regional partners as the outbreak continues in the Democratic Republic of Congo.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
GSK has announced a 1.9 billion cost-cutting programme and a shift of more than 1,000 scientists to a new Cambridge R&D campus from Stevenage by 2029, part of broader plans to cut costs and expand late-stage trials.
EY has warned the UK economy could slip into recession if Hormuz remains closed, while a reopening could keep growth resilient at 0.9% in 2026 and 1.2% in 2027. The outlook shifts with oil prices easing and talks of a potential AstraZeneca–BMS merger, set against a backdrop of manufacturing activity data and a stretched timetable for a takeover.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
A roundup of recent reports shows how debt, housing costs, and consumer spend patterns shape the US financial landscape. Redfin and Zillow data indicate ongoing affordability stress in housing, while consumer debt and money-management trends are highlighted by CNBC and independent outlets. The mix suggests a cautious, debt-aware economy.
AstraZeneca has not confirmed talks with Bristol Myers Squibb on a potential $400bn mega-merger, despite earlier reports. The markets rallied and fell as investors digest the possibility, with analysis suggesting mega-deals face antitrust and integration risks. AZ’s strategy centers on accelerating U.S. presence while leveraging its strong oncology franchise.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.
Stocks waver as Walmart’s earnings miss dulls confidence; higher oil prices and rising yields weigh on sentiment. Treasuries signal caution as investors assess consumer resilience amid inflationary pressure.
Two unvaccinated residents in Pennsylvania have died from measles, triggering a public health debate. Governor Shapiro says vaccinations could have averted the deaths, while RFK Jr. questions the figures, fueling a political row that experts warn could hinder responses to the outbreak.
The FDA has approved daraxonrasib (Rasonque), a once-daily pill from Revolution Medicines, for adults with metastatic pancreatic cancer who have received prior therapy or cannot take combination chemotherapy. A 500‑patient trial has shown median survival of 13.2 months versus 6.7 months for chemotherapy; a 30‑day supply will cost about $39,800 and expanded access has already treated thousands.